Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods

Tillmann Taube; Cornelia Eckert; Gabriele Körner; Günter Henze; Karlheinz Seeger

doi:10.1016/j.leukres.2003.11.006

Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods

Leuk Res. 2004 Jul;28(7):699-706. doi: 10.1016/j.leukres.2003.11.006.

Authors

Tillmann Taube¹, Cornelia Eckert, Gabriele Körner, Günter Henze, Karlheinz Seeger

Affiliation

¹ Klinik für Pädiatrie mit Schwerpunkt Onkologie/Hämatologie, Otto-Heubner Centrum für Kinder- und Jugendmedizin, Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin, Forschungshaus 37, 3353 Berlin, Germany. tillmann.taube@charite.de

PMID: 15158091
DOI: 10.1016/j.leukres.2003.11.006

Abstract

Response to therapy of ALL assessed by molecular methods has been proved to be a predictor of outcome. Alternatively to established but very labour-intensive DNA-based PCR-techniques the TEL-AML1 fusion transcript can serve as a marker for MRD monitoring. MRD quantification using TEL-AML1 is of particular interest if the results are directly comparable to data obtained by established DNA-based assays. Investigation of the potential of MRD monitoring using LightCycler technology for TEL-AML1 real-time quantification and comparison to results from established DNA-based MRD assays revealed corresponding results. Accordingly, TEL-AML1 MRD quantification is a sensitive, specific and rapid method that can supplement clone-specific MRD detection.

Publication types

Comparative Study
Evaluation Study
Research Support, Non-U.S. Gov't

MeSH terms

Bone Marrow / pathology
Child
Core Binding Factor Alpha 2 Subunit
Fluorescence
Humans
Molecular Diagnostic Techniques / methods
Molecular Diagnostic Techniques / standards
Neoplasm, Residual / diagnosis*
Neoplasm, Residual / genetics
Oncogene Proteins, Fusion / genetics*
Polymerase Chain Reaction / methods*
Polymerase Chain Reaction / standards
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
RNA, Messenger / analysis*
Receptors, Antigen / analysis
Recurrence
Sensitivity and Specificity

Substances

Core Binding Factor Alpha 2 Subunit
Oncogene Proteins, Fusion
RNA, Messenger
Receptors, Antigen
TEL-AML1 fusion protein